Asthma is a common comorbid condition in sickle cell disease (SCD). However, obstructive lung disease is prevalent in SCD, independent of a diagnosis of asthma. It is speculated that the heightened state of inflammation in SCD, involving pathways distinct from allergic asthma, may underlie the SCD-specific obstructive disease.
Objective:
The objective of the study was to compare airway and systemic inflammatory markers between SCD patients with pulmonary manifestations and patients with allergic asthma, and correlate the discriminating inflammatory markers with clinical measures of pulmonary disease.
Materials and Methods:
In a pilot translational study conducted at the Children's Hospital at Montefiore, 15 patients with SCD, and history of asthma, airway obstruction, or airway hyper-reactivity, and 15 control patients with allergic asthma 6–21 years of age were recruited. Inflammatory markers, including peripheral blood T helper cell subsets, serum and exhaled breath condensate (EBC) cytokines and chemokines of the Th-1/Th-17, Th-2, and monocytic pathways, and serum cysteinyl leukotrienes B4 (LTB4), were quantified, compared between the study groups, and correlated with atopic sensitization, pulmonary function tests, and markers of hemolysis.
Results:
White blood cells (P < 0.05) and monocytes (P < 0.001) were elevated in the SCD group, while atopic characteristics were higher in the control asthma group. Tumor necrosis factor-alpha (P < 0.01), interferon gamma inducible protein (IP)-10 (P < 0.05), and interleukin-4 (P < 0.01) in serum and monocyte chemotactic protein (MCP)-1 in EBC were higher in the SCD group (P ≤ 0.05). Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) in patients with SCD inversely correlated with serum IP-10 and LTB4 levels.
Conclusions:
Compared with atopic asthmatic patients, inflammatory markers involving Th-1, Th-2, and monocytic pathways were higher in the SCD group, among which Th-1 measures correlated with pulmonary function deficits.
Get full access to this article
View all access options for this article.
References
1.
CDC. Data and Statistics | Sickle Cell Disease | NCBDDD | CDC. Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/sicklecell/data.html. Published August 31, 2016. (last accessed November3, 2017).
2.
BoydJH, MoinuddinA, StrunkRC, et al.Asthma and acute chest in sicklecell disease. Pediatr Pulmonol, 2004; 38:229–232.
3.
BryantR. Asthma in the pediatric sickle cell patient with acute chest syndrome. J Pediatr Health Care, 2005; 19:157–162.
4.
BoydJH, MacklinEA, StrunkRC, et al.Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood, 2006; 108:2923–2927.
5.
Knight-MaddenJM, ForresterTS, LewisNA, et al.Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax, 2005; 60:206–210.
6.
FieldJJ, DeBaunMR. Asthma and sickle cell disease: two distinct diseases or part of the same process?. Hematology Am Soc Hematol Educ Program, 2009; 6:45–53.
7.
GlassbergJ, SpiveyJF, StrunkR, et al.Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol, 2006; 28:481–485.
8.
SylvesterKP, PateyRA, BroughtonS, et al.Temporal relationship of asthma to acute chest syndrome in sickle cell disease. Pediatr Pulmonol, 2007; 42:103–106.
9.
RossJGC, BernaudinF, StrunkRC, et al.Asthma is a distinct comorbid condition in children with sickle cell anemia with elevated total and allergen-specific IgE levels. J Pediatr Hematol Oncol, 2011; 33:e205–e208.
10.
YadavA, Corrales-MedinaFF, StarkJM, et al.Application of an asthma screening questionnaire in children with sickle cell disease. Pediatr Allergy Immunol Pulmonol, 2015; 28:177–182.
11.
ChaudryRA, RosenthalM, BushA, et al.Reduced forced expiratory flow but not increased exhaled nitric oxide or airway responsiveness to methacholine characterises paediatric sickle cell airway disease. Thorax, 2014; 69:580–585.
12.
PaulR, MinnitiCP, NouraieM, et al.Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur J Haematol, 2013; 91:62–68.
13.
RosenCL, DebaunMR, StrunkRC, et al.Obstructive sleep apnea and sickle cell anemia. Pediatrics, 2014; 134:273–281.
14.
BloomB, CohenRA, FreemanG. Summary health statistics for u.s. Children: national health interview survey, 2011. Vital Health Stat, 2012; 10:1–88.
15.
KoumbourlisAC, ZarHJ, Hurlet-JensenA, et al.Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr, 2001; 138:188–192.
ShiloNR, AlawadiA, Allard-CoutuA, et al.Airway hyperreactivity is frequent in non-asthmatic children with sickle cell disease. Pediatr Pulmonol, 2016; 51:950–957.
18.
OzbekOY, MalboraB, SenN, et al.Airway hyperreactivity detected by methacholine challenge in children with sickle cell disease. Pediatr Pulmonol, 2007; 42:1187–1192.
19.
FieldJJ, StocksJ, KirkhamFJ, et al.Airway hyperresponsiveness in children with sickle cell anemia. Chest, 2011; 139:563–568.
20.
PlattOS, BrambillaDJ, RosseWF, et al.Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med, 1994; 330:1639–1644.
21.
DeBaunMR, StrunkRC. The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia. Lancet Lond Engl, 2016; 387:2545–2553.
22.
ManwaniD, FrenettePS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood, 2013; 122:3892–3898.
23.
ZhangD, XuC, ManwaniD, et al.Neutrophils, platelets, and inflammatory pathways, at the nexus of sickle cell disease pathophysiology. Blood, 2016; 127:801–809.
NandedkarSD, FeroahTR, HutchinsW, et al.Histopathology of experimentally induced asthma in a murine model of sickle cell disease. Blood, 2008; 112:2529–2538.
26.
AndemariamB, AdamiAJ, SinghA, et al.The sickle cell mouse lung: proinflammatory and primed for allergic inflammation. Transl Res J Lab Clin Med, 2015; 166:254–268.
27.
WallaceKL, MarshallMA, RamosSI, et al.NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood, 2009; 114:667–676.
28.
NewaskarM, HardyKA, MorrisCR. Asthma in sickle cell disease. Sci World J, 2011; 11:1138–1152.
29.
OpeneM, Kurantsin-MillsJ, HusainS, et al.Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: relevance in the pathology of the acute chest syndrome. Pulm Circ, 2014; 4:482–495.
30.
CrapoRO, HankinsonJL, IrvinC, et al.Standardization of spirometry, 1994 update. American thoracic society. Am J Respir Crit Care Med, 1995; 152:1107–1136.
31.
American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med, 2002; 166:518–624.
32.
American ThoracicSociety, European RespiratorySociety. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med, 2005; 171:912–930.
33.
BelcherJD, MarkerPH, WeberJP, et al.Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 2000; 96:2451–2459.
34.
WongtongN, JonesS, DengY, et al.Monocytosis is associated with hemolysis in sickle cell disease. Hematology, 2015; 20:593–597.
35.
WunT, CordobaM, RangaswamiA, et al.Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol, 2002; 24:81–88.
36.
SafayaS, SteinbergMH, KlingsES. Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF-κB signaling pathway. Mol Immunol, 2012; 50:117–123.
37.
SettyBNY, KeyNS, RaoAK, et al.Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol, 2012; 157:370–380.
38.
SultanaC, ShenY, RattanV, et al.Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood, 1998; 92:3924–3935.
39.
NeumannF-J, OttI, MarxN, et al.Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol, 1997; 17:3399–3405.
40.
PerelmanN, SelvarajSK, BatraS, et al.Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood, 2003; 102:1506–1514.
41.
SelvarajSK, GiriRK, PerelmanN, et al.Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood, 2003; 102:1515–1524.
42.
PatelN, GonsalvesCS, YangM, et al.Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood, 2009; 113:1129–1138.
43.
Eiymo Mwa MpolloM-S, BrandtEB, ShanmukhappaSK, et al.Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest, 2016; 126:571–584.
44.
AnP, Barron-CasellaEA, StrunkRC, et al.Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity. J Allergy Clin Immunol, 2011; 127:1440–1446.
45.
RastogiD, ReddyM, NeugebauerR. Comparison of patterns of allergen sensitization among inner-city Hispanic and African American children with asthma. Ann Allergy Asthma Immunol, 2006; 97:636–642.
46.
KronenbergM, GapinL. The unconventional lifestyle of NKT cells. Nat Rev Immunol, 2002; 2:557–568.
47.
CharacheS, BartonFB, MooreRD, et al.Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore), 1996; 75:300–326.
48.
ThanabalasuriarA, NeupaneAS, WangJ, et al.iNKT cell emigration out of the lung vasculature requires neutrophils and monocyte-derived dendritic cells in inflammation. Cell Rep, 2016; 16:3260–3272.
49.
GlassbergJ, MinnittiC, CromwellC, et al.Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple-blind, randomized trial. Am J Hematol, 2017; 92:622–631.
50.
SantoliF, ZerahF, VasileN, et al.Pulmonary function in sickle cell disease with or without acute chest syndrome. Eur Respir J, 1998; 12:1124–1129.
51.
KlingsES, WyszynskiDF, NolanVG, et al.Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med, 2006; 173:1264–1269.
52.
ArtetaM, CampbellA, NouraieM, et al.Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol, 2014; 36:185–189.
53.
HughesJMB, PrideNB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med, 2012; 186:132–139.
54.
LuntA, McGheeE, RobinsonP, et al.Lung function, transfusion, pulmonary capillary blood volume and sickle cell disease. Respir Physiol Neurobiol, 2016; 222:6–10.
55.
MillerGJ, SerjeantGR. An assessment of lung volumes and gas transfer in sickle-cell anaemia. Thorax, 1971; 26:309–315.
56.
SullivanKJ, KissoonN, DuckworthLJ, et al.Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med, 2001; 164:2186–2190.
57.
GirgisRE, QureshiMA, AbramsJ, et al.Decreased exhaled nitric oxide in sickle cell disease: relationship with chronic lung involvement. Am J Hematol, 2003; 72:177–184.
58.
RadhakrishnanDK, BendiakGN, Mateos-CorralD, et al.Lower airway nitric oxide is increased in children with sickle cell disease. J Pediatr, 2012; 160:93–97.
59.
Knight-MaddenJ, VerganiD, PateyR, et al.Cytokine levels and profiles in children related to sickle cell disease and asthma status. J Interferon Cytokine Res, 2012; 32:1–5.
60.
AhmadzaiH, HuangS, HettiarachchiR, et al.Exhaled breath condensate: a comprehensive update. Clin Chem Lab Med, 2013; 51:1343–1361.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
